We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 41ON market cap is 0. The company's latest EPS is USD -0.2896 and P/E is -6.84.
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -36.84M | -51.77M | -63.12M | -53.14M | -71.8M |
| Net Income | -48.87M | -53.16M | -66.05M | -58.98M | -75.37M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 19.73M | 22.81M | 28.53M | 32.3M | 28.82M |
| Total Liabilities | 16.91M | 18.2M | 19.79M | 46.74M | 101.9M |
| Total Equity | 2.83M | 4.61M | 8.74M | -14.44M | -73.08M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.79M | -54.25M | -56.67M | -42.97M | -68.79M |
| Investing | -900k | N/A | N/A | N/A | N/A |
| Financing | 37.21M | 56.19M | 59.59M | 48.97M | 60.33M |
| Market Cap | 0 |
| Price to Earnings Ratio | -6.84 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 34.49 |
| Price to Book Ratio | -7.05 |
| Dividend Yield | - |
| Shares Outstanding | 260.26M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 0.462 |
| 52 Week Low | 0.308 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Outlook Therapeutics Inc |
| Address |
800 north state street dover, delaware 19901 |
| Website | https://www.outlooktherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
